{
    "2020-10-31": [
        [
            {
                "time": "",
                "original_text": "【浙商医药|点评】泰格医药：Q3 加速恢复，不仅仅临床业务，看好多业务边际改善",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q3",
                        "加速恢复",
                        "临床业务",
                        "多业务",
                        "边际改善"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【天风医药】泰格医药：前三季度公司业绩稳健增长，H股上市提升国际化",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "前三季",
                        "业绩稳健增长",
                        "H股上市",
                        "国际化"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}